Subbiah Ishwaria M, Gonzalez-Angulo Ana Maria
Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030-4009, USA.
Curr Treat Options Oncol. 2014 Mar;15(1):41-54. doi: 10.1007/s11864-013-0262-4.
The natural history of HER2-positive breast cancer significantly changed in the past 15 years. Form being the most aggressive type of breast cancer, it became treatable with important cure rates. However, with new and successful drugs, resistance emerges. Progress in research and drug development continues to make available effective anti-HER2 therapies. Our challenge today is to use these tools correctly by looking at the data that support the indications of each compound and to continue clinical trial participation.
在过去15年中，HER2阳性乳腺癌的自然病程发生了显著变化。它曾是最具侵袭性的乳腺癌类型，如今已可通过重要的治愈率进行治疗。然而，随着新的成功药物的出现，耐药性也随之产生。研究和药物开发的进展继续提供有效的抗HER2疗法。我们如今面临的挑战是通过审视支持每种化合物适应证的数据来正确使用这些工具，并继续参与临床试验。
